Key result
NOACs linked to ~43% lower mortality and less minor bleeding vs warfarin in older AF patients.
Why the study?
Stroke prevention in elderly AF patients is challenging, and real-world clinical comparisons of NOACs versus warfarin in elderly Asian patients have not been well studied.
Do NOACs reduce bleeding, thrombosis, and mortality in elderly patients (≥65 years) with atrial fibrillation compared to warfarin?
Population
3450 elderly patients with AF (≥ 65 years of age) across 4 centers in China
Comparison
NOACs (dabigatran, rivaroxaban, apixaban, or edoxaban) vs warfarin
Design
Retrospective multicenter cohort study
Follow-up
Average of 15 months
Authors
Loading...
May favor NOACs over warfarin in elderly Asian AF; leaves open confirmation by randomized trials.
Cohort (n=3,450)
Yes
Do NOACs reduce bleeding, thrombosis, and mortality in elderly patients (≥65 years) with atrial fibrillation compared to warfarin?
Effect estimate: OR 0.57 (95% CI 0.44-0.75)
Absolute Event Rate: 8.92% vs 12.85%
p-value: p=<0.001
In real-world elderly Asian patients with atrial fibrillation, NOACs were associated with a reduced risk of minor bleeding and all-cause mortality compared to warfarin, with similar rates of thromboembolism and major bleeding.
Lan et al. (2025) conducted a cohort in Atrial fibrillation (n=3,450). NOACs vs. Warfarin was evaluated on All-cause mortality (OR 0.57, 95% CI 0.44-0.75, p=<0.001). NOACs significantly reduced the risk of all-cause mortality (OR 0.57) and minor bleeding (OR 0.70) compared to warfarin in atrial fibrillation patients aged 65 years and older.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: